Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 7/20 | 0.38 |
| ▸ | PRKDC | P78527 | 4/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.35 |
| ▸ | LPL | P06858 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | STK4 | Q13043 | 1/20 | 0.33 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29775060 | 0.80 | EGFR (0.60) | AREGFRPRKDCLRRK2PIK3CA | |
| SCHEMBL29775065 | 0.80 | EGFR (0.60) | AREGFRPRKDCLRRK2PIK3CA | |
| SCHEMBL24576517 | 0.80 | EGFR (0.60) | AREGFRPRKDCLRRK2PIK3CA | |
| SCHEMBL25606443 | 0.79 | EGFR (0.46) | EGFRLPLLIPGIDO1TDO2 | |
| SCHEMBL18171863 | 0.76 | LPL (0.37) | ARPGREGFRESR2LPL | |
| SCHEMBL20445884 | 0.74 | RPS6KB1 (0.49) | ARPGREGFRESR2LPL | |
| SCHEMBL20445886 | 0.74 | RPS6KB1 (0.49) | ARPGREGFRESR2LPL | |
| SCHEMBL24576518 | 0.74 | EGFR (0.49) | AREGFRPRKDCLRRK2PIK3CA | |
| SCHEMBL24576528 | 0.72 | EGFR (0.47) | AREGFRPRKDCLRRK2PIK3CA | |
| SCHEMBL29133792 | 0.72 | PDPK1 (0.42) | EGFRPRKDCLRRK2MAP3K8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239764-A1 | SUBSTITUTED AMINOBENZYL HETEROARYL COMPOUNDS AS EGFR AND/OR PI3K INHIBITORS | EGFR, ERBB2, ERBB3 | AR 209/4885PGR 570/4885EGFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.